Dominik Dannehl

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort study.

The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort study.

Journal: Archives of gynecology and obstetrics

Published: December 12, 2025

Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area.

Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area.

Journal: Archives of gynecology and obstetrics

Published: December 12, 2025

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

Journal: NPJ breast cancer

Published: November 29, 2025

Choriocarcinoma: Navigating risk, resistance, and remarkable curability.

Choriocarcinoma: Navigating risk, resistance, and remarkable curability.

Journal: Case reports in women's health

Published: November 28, 2025

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Journal: Breast cancer research and treatment

Published: October 24, 2025

High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany.

High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany.

Journal: Geburtshilfe und Frauenheilkunde

Published: July 20, 2025

Management and natural course of CIN 1 and CIN 2 before and after implementation of the revised cervical cancer screening in Germany.

Management and natural course of CIN 1 and CIN 2 before and after implementation of the revised cervical cancer screening in Germany.

Journal: Archives of gynecology and obstetrics

Published: July 15, 2025

Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.

Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.

Journal: Geburtshilfe und Frauenheilkunde

Published: July 12, 2025

Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.

Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.

Journal: Archives of gynecology and obstetrics

Published: May 28, 2025

Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.

Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.

Journal: Archives of gynecology and obstetrics

Published: May 28, 2025

Therapy of early breast cancer: current status and perspectives.

Therapy of early breast cancer: current status and perspectives.

Journal: Archives of gynecology and obstetrics

Published: February 17, 2025

Association of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer.

Association of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer.

Journal: Cancer letters

Published: February 17, 2025

Showing 1-12 of 40

Last Updated: 09/26/2026